Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company's aim of transforming the lives of people with cancer .   Boehringer Ingelheim strengthens footprintin Swiss biotech innovation hub .  Basel, Switzerland, Thursday, 03 .04.2025 – Today NBETherapeutics (NBE)a wholly owned subsidiary of   Boehringer...

Ingelheim am Rhein, 03/04/2025 (informazione.news - comunicati stampa - salute e benessere)